Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
1 INTRODUCTION Zuranolone (SAGE-217) was submitted to the Food and Drug Administration (FDA) for marketing approval in the United States for major depressive disorder (MDD) and for postpartum depression (PPD) in 2022.
On November 8, 2021, Sonja Styblo spoke to the Joint Committee on Mental Health Substance and Use and Recovery in Massachusetts legislature to lobby for the passage of Benzodiazepine Bills S. 1260 and H.2117: An Act Relative to Benzodiazepines and Non-benzodiazepine Hypnotics. Her opening message was straightforward: “We are here speaking truth to power today.” Sonja Styblo Styblo has been urging the Massachusetts Legislature to pass this bill for years now.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
